Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Completed 7Not yet recruiting 5Active not recruiting 5Recruiting 4Unknown 3Terminated 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4

Conditions

Colorectal Neoplasms 44Pancreatic Neoplasms 17Stomach Neoplasms 16Neoplasm Metastasis 11Rectal Neoplasms 10Neoplasms 10Colonic Neoplasms 7Adenocarcinoma 7Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Gastrointestinal Neoplasms 5Biliary Tract Neoplasms 5Esophageal Neoplasms 4Cholangiocarcinoma 4Burkitt Lymphoma 4Advanced Solid Tumors 4Adenocarcinoma Of Esophagus 4Leukemia, Biphenotypic, Acute 3Esophageal Squamous Cell Carcinoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Peritoneal Neoplasms 2Ovarian Neoplasms 2Locally Recurrent Rectal Cancer 2Gallbladder Neoplasms 2Endometrial Neoplasms 2Appendiceal Neoplasms 2Uterine Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Solid Tumors 1

Interventions

Gemcitabine 21Cisplatin 16durvalumab 12lenvatinib 11Oxaliplatin 11pembrolizumab 6Liver Transplantation 4Leucovorin 4Floxuridine 4tislelizumab 3Nivolumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Fluorouracil 3Drug Therapy 3Capecitabine 3Biopsy 3tremelimumab 2pemigatinib 2olaparib 2ivosidenib 2irinotecan sucrosofate 2apatinib 2Taxes 2Specimen Handling 2Injections 2Immunoglobulin G 2Immune Checkpoint Inhibitors 2Fluorodeoxyglucose F18 2Disulfides 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × Cholangiocarcinoma × Leucovorin × Clear all
NCT04421820 2026-05-18

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours

Bold Therapeutics, Inc.

Phase 1/2 Recruiting
220 enrolled
Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT07265674 2026-05-14

Beacon-BTC

J-Pharma Co., Ltd.

Phase 3 Recruiting
480 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT07025174 2025-06-17

SAIB

First Affiliated Hospital of Zhejiang University

Phase 2 Recruiting
60 enrolled
Gastrointestinal

Bile Duct Neoplasms, Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT06438822 2025-05-07

Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma

West China Hospital

Phase 2 Recruiting
51 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡